Back to discover
Disease

Hepatic Encephalopathy

Late-stage therapeutic developmentEmerging research
MeSHHepatic Encephalopathy
2
Publications
18
Clinical trials
2019
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 2 clinical trials expected to report results, the earliest in Q4 2026.
Upcoming Milestones
Clinical Milestones4View
Results expected 2
Recently completed 2
Activity timeline4

Clinical trials

18 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
18
All trials
6
Active
15
Late-stage
6
Completed
Late-stage studies

Clinical Study Evaluating the Efficacy and Safety of Nitazoxanide in Preventing Recurrence of Hepatic Encephalopathy

Phase 3 · Recruiting · Tanta University

Branch Chain Amino Acids vs. Rifaximin in Patients With Cirrhosis for Secondary Prophylaxis of Hepatic Encephalopathy: Double-blind Placebo-controlled Multicentric Randomized Controlled Trial

Phase 4 · Recruiting · Post Graduate Institute of Medical Education and Research, Chandigarh

Prevention of Hepatic Encephalopathy by Administration of Rifaximin and Lactulose in Patients With Liver Cirrhosis Undergoing TIPS Placement: a Multi-centre Randomized, Double Blind, Placebo Controlled Trial.

Phase 4 · Recruiting · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Inhaled Amikacin as a Prophylaxis for Ventilator Associated Pneumonia in Patients With Cirrhosis: A Randomized Placebo Controlled Double Blind Study

Phase 4 · Recruiting · Asian Institute of Gastroenterology, India

Comparison of Efficacy of Rifaximin, Probiotics and LOLA (L-Ornithine L-Aspartate) in Overt Hepatic Encephalopathy: A Randomized, Phase-IV, Lactulose Controlled Clinical Trial.

Phase 4 · Completed · Qurratul Ain Jamil

Low-dose Rifaximin in the Treatment of Covert Hepatic Encephalopathy: A Randomized Open Controlled Study

Phase 4 · Completed · Shanghai Changzheng Hospital
Recruiting

Clinical Study Evaluating the Efficacy and Safety of Nitazoxanide in Preventing Recurrence of Hepatic Encephalopathy

Phase 3 · Recruiting · Tanta University

Branch Chain Amino Acids vs. Rifaximin in Patients With Cirrhosis for Secondary Prophylaxis of Hepatic Encephalopathy: Double-blind Placebo-controlled Multicentric Randomized Controlled Trial

Phase 4 · Recruiting · Post Graduate Institute of Medical Education and Research, Chandigarh

Randomized Clinical Trial in Hepatic Encephalopathy to Study Lasting Cognitive Improvement With Intravenous Albumin

Phase 2 · Recruiting · Hunter Holmes Mcguire Veteran Affairs Medical Center

Human Albumin Infusion in Liver Cirrhosis and Overt Hepatic Encephalopathy (HACHE): an Invesitgator-initiated, Open-label, Multicenter, Randomized Controlled Trial

N/A · Recruiting · General Hospital of Shenyang Military Region

Prevention of Hepatic Encephalopathy by Administration of Rifaximin and Lactulose in Patients With Liver Cirrhosis Undergoing TIPS Placement: a Multi-centre Randomized, Double Blind, Placebo Controlled Trial.

Phase 4 · Recruiting · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Inhaled Amikacin as a Prophylaxis for Ventilator Associated Pneumonia in Patients With Cirrhosis: A Randomized Placebo Controlled Double Blind Study

Phase 4 · Recruiting · Asian Institute of Gastroenterology, India
Recently completed

Efficacy and Safety of Nifuroxazide in the Treatment of Hepatic Encephalopathy in Egyptian Patients With Liver Cirrhosis

Phase 3 · Completed · Cairo University

Comparison of Efficacy of Rifaximin, Probiotics and LOLA (L-Ornithine L-Aspartate) in Overt Hepatic Encephalopathy: A Randomized, Phase-IV, Lactulose Controlled Clinical Trial.

Phase 4 · Completed · Qurratul Ain Jamil

Efficacy of L-Ornithine L-Aspartate (LOLA) as an Adjunct to Branched Chain Amino Acids (BCAA) Enriched Solutions on Clinical Outcomes in ICU Patients With Hepatic Encephalopathy: a Randomized Controlled Trial

Phase 4 · Completed · Ain Shams University

Low-dose Rifaximin in the Treatment of Covert Hepatic Encephalopathy: A Randomized Open Controlled Study

Phase 4 · Completed · Shanghai Changzheng Hospital

Rifaximin and Its Microbial Resistance as a Secondary Prophylaxis of Hepatic Encephalopathy in Patients With HCV Related Cirrhosis

Phase 4 · Completed · National Hepatology & Tropical Medicine Research Institute

Efficacy of Intravenous 'L-ornithine L-aspartate' in Reversal of Overt Acute Hepatic Encephalopathy in Patients With Liver Cirrhosis: a Prospective, Randomized, Double-blind, Placebo Controlled Trial

Phase 4 · Completed · Dayanand Medical College and Hospital

Research activity

2 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
20142019
Leading journals2
  • Hepatology (Baltimore, Md.)1
  • The New England journal of medicine1
Leading researchers8
  • Amodio P1
  • Bajaj J1
  • Bloom PP1
  • Chen YB1
  • Chung RT1
  • Cordoba J1
  • DeFilipp Z1
  • Ferenci P1
Affiliations (unnormalised)2
  • Aarhus University Hospital1
  • the Liver Center1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

A syndrome characterized by central nervous system dysfunction in association with LIVER FAILURE, including portal-systemic shunts. Clinical features include lethargy and CONFUSION (frequently progressing to COMA); ASTERIXIS; NYSTAGMUS, PATHOLOGIC; brisk oculovestibular reflexes; decorticate and decerebrate posturing; MUSCLE SPASTICITY; and bilateral extensor plantar reflexes (see REFLEX, BABINSKI). ELECTROENCEPHALOGRAPHY may demonstrate triphasic waves. (From Adams et al., Principles of Neurology, 6th ed, pp1117-20; Plum & Posner, Diagnosis of Stupor and Coma, 3rd ed, p222-5)

Identifiers
MeSHHepatic Encephalopathy
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.